ARCA biopharma, Inc. (NASDAQ:ABIO) Major Shareholder Henderson Group Plc Janus Acquires 166,042 Shares

ARCA biopharma, Inc. (NASDAQ:ABIO) major shareholder Henderson Group Plc Janus acquired 166,042 shares of ARCA biopharma stock in a transaction dated Wednesday, July 3rd. The shares were acquired at an average price of $3.55 per share, with a total value of $589,449.10. Following the transaction, the insider now owns 1,648,577 shares in the company, valued at approximately $5,852,448.35. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Henderson Group Plc Janus also recently made the following trade(s):

• On Wednesday, July 10th, Henderson Group Plc Janus acquired 55,463 shares of ARCA biopharma stock. The shares were acquired at an average price of $3.46 per share, with a total value of $191,901.98.
• On Monday, July 8th, Henderson Group Plc Janus acquired 47,492 shares of ARCA biopharma stock. The shares were acquired at an average price of $3.46 per share, with a total value of $164,322.32.
• On Friday, July 5th, Henderson Group Plc Janus acquired 28,326 shares of ARCA biopharma stock. The shares were acquired at an average price of $3.43 per share, with a total value of $97,158.18.

ARCA biopharma Trading Up 0.9 %

Shares of ABIO traded up $0.03 during midday trading on Friday, hitting $3.35. The stock had a trading volume of 14,055 shares, compared to its average volume of 713,609. ARCA biopharma, Inc. has a fifty-two week low of $1.56 and a fifty-two week high of $4.49. The business has a 50-day simple moving average of $3.43 and a two-hundred day simple moving average of $2.54. The firm has a market cap of $48.61 million, a P/E ratio of -7.98 and a beta of 0.90.

ARCA biopharma (NASDAQ:ABIO) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($0.14) EPS for the quarter.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of ARCA biopharma in a research report on Wednesday, May 22nd. They set a “sell” rating for the company.

Institutional Trading of ARCA biopharma

A hedge fund recently bought a new stake in ARCA biopharma stock. abrdn plc purchased a new position in shares of ARCA biopharma, Inc. (NASDAQ:ABIO) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 32,461 shares of the biopharmaceutical company’s stock, valued at approximately $55,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About ARCA biopharma

ARCA biopharma, Inc, a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure.